Chemical sales reach $14.2b. in '05

Sales were broken into exports which increased by 18% to $7.6b., and local sales which were 2% higher than 2004 at $6.6b.

By AVI KRAWITZ
February 9, 2006 06:37

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

The chemical and pharmaceuticals sector proved to be Israel's biggest growth industry in 2005 as total sales grew 10 percent to $14.2 billion from 2004, the Israel Manufacturers Association (IMA) said Wednesday. Sales were broken into exports which increased by 18% to $7.6b., and local sales which were 2% higher than 2004 at $6.6b. "Last year was the most successful year in more than a decade for Israeli pharmaceuticals," said Yosef Barnea, Chairman of the Chemicals and Pharmaceuticals division of IMA. "2006 can be even better."

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS